Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Geovax Labs

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies and vaccines against cancers and infectious diseases using a novel vector vaccine platform. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus (HIV), as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

GeoVax Labs advances cancer therapies and COVID-19 vaccine development

GeoVax Labs showcased advancements in cancer therapies and COVID-19 vaccine development, underlining a commitment to innovation and global healthcare improvement.
While facing financial challenges due to increased R&D expenses and net loss, GeoVax's strategic strengths in vaccine development and clinical trials offer promising opportunities for growth.
The completion of the Gedeptin trial, ongoing Phase II trials for CM04S1, and plans for future vaccine developments position GeoVax for impactful contributions to healthcare.

GeoVax Labs reports Q2 loss, progresses in key trials

GeoVax's Q2 performance reflects ongoing investment in R&D and progress in key clinical trials.
The company's strengths lie in securing funding, commitment to innovation, and vaccine differentiation.
Challenges include recruitment issues, funding needs, and uncertainties in the pipeline.
Opportunities exist in fundraising, vaccine development, expanding indications, and optimizing clinical trials.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Atlanta, GA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today the closing of its previously announced private placement for the issuance and sale of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock, and accompanying warrants to purchase an aggregate of up to 3,067,484 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with an accompanying warrant at a combined effective purchase price of $3.26. The warrants are exercisable immediately at an exercise price of $3.26 per share and will expire five years from the date of issuance.

GeoVax Announces Closing of $10 Million Private Placement

Atlanta, GA, Jan. 14, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock and accompanying warrants to purchase an aggregate of up to 3,067,484 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with an accompanying warrant at a combined effective purchase price of $3.26. The warrants will be exercisable immediately at an exercise price of $3.26 per share and will expire five years from the date of issuance. The closing of the private placement is expected to occur on January 19, 2022, subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreement.

GeoVax Announces $10 Million Private Placement

Activities Underway to Expand and Accelerate Enrollment of Ongoing Study for Head and Neck Cancer

GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial

Atlanta, GA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H., to serve as the Company's Chief Medical Officer (CMO).

GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer

Letter from CEO Describes Achievements during 2021 and Sets Forth New Goals for 2022

GeoVax Issues Shareholder Update Letter

GOVX is uniquely positioned with its Phase 2 COVID-19 vaccine candidate for immunocompromised individuals. It has also started a Phase 2 trial as a booster vaccine for the general population. In addition to its GEO/COH04S1 and GEO-CM02 COVID-19 vaccine candidates, it has clinical trials on HIV and early stage candidates for a variety of infectious diseases, funded through non-dilutive sources.

GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation

GeoVax Labs Inc (NASDAQ: GOVX) initiated vaccine dosing in the Phase 2 portion of its Phase 1/2 trial of COH04S1 COVID-19 vaccine to target both the spike (S) and nucleocapsid (N) proteins. The Phase 1 portion of the trial was designed as a dose-escalation safety study in healthy adult individuals aged 18 to 55 who had not been previously infected with SARS-CoV-2.

GeoVax Initiates Phase 2 Trial For COVID-19 Vaccine Booster

Shares of GeoVax Labs Inc. GOVX, -1.76% were down 1.4% in trading on Wednesday after the company said it began a Phase 2 clinical trial for its COVID-19 booster candidate.

GeoVax initiates Phase 2 clinical trial for its experimental COVID-19 booster

Ongoing Phase 1/2 Trial Advancing to Phase 2 Evaluation of Multi-Antigen Vaccine, Targeting both Spike and Nucleocapsid Proteins, as a Universal Booster to Current FDA-Approved Vaccines

GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster

Nonhuman Primate Testing of Sudan and Marburg Vaccine Candidates Demonstrates Efficacious Immune Response

GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress

GEO-CM02 Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants such as Omicron

GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress

Chembio Diagnostics

iBio

NovaBay Pharmaceuticals

Oragenics

SINTX Technologies Inc

XpresSpa Group

Hot penny stocks to watch as new virus fears emerge on Black Friday. The post Hot Penny Stocks To Buy?

Hot Penny Stocks To Buy? 7 To Watch As African Variant Shakes Markets

The stock price of Geovax Labs Inc (NASDAQ: GOVX) increased by over 35% pre-market today. This is why it happened.

Geovax Labs (GOVX) Stock: Why The Price Surged Today

GEO-CM02 Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants

GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress

The stock price of Geovax Labs Inc (NASDAQ: GOVX) increased by over 14% during intraday trading today. This is why it happened.

Geovax Labs (GOVX) Stock: Why The Price Jumped Today

GeoVax Labs Inc (NASDAQ: GOVX) has received a U.S. patent covering its vector platform for expressing tumor-associated antigens in virus-like particles (VLPs). The platform comes from a Modified Vaccinia Ankara (MVA) viral vector and encompasses GeoVax's Mucin 1 (MUC1) tumor-associated antigen immunotherapy candidate.

GeoVax Shares Surge After Cancer Vaccine Patent In US

GeoVax Labs, Inc. (NASDAQ: GOVX), a biotechnology company developing human immunotherapies and vaccines…

GeoVax Labs, Inc. (NASDAQ: GOVX) Receives Notice of Allowance For Cancer Vaccine Patent

GeoVax Intellectual Property Portfolio Includes More than 70 Granted/Pending Patent Applications

GeoVax Receives Notice of Allowance for Cancer Vaccine Patent

GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q3 2021 Results - Earnings Call Transcript

Progress in Clinical Development of COVID-19 and Immuno-Oncology Programs

GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update

GeoVax Labs Inc (NASDAQ: GOVX) entered into an exclusive license agreement with City of Hope, a cancer research and treatment organization, for COH04S1, a synthetic, attenuated modified vaccinia Ankara vector expressing spike and nucleocapsid antigens of the SARS-CoV-2 virus.  GeoVax has exclusive rights to develop and commercialize a multi-antigenic SARS-CoV-2 vaccine candidate developed at the City of Hope for immunocompromised patients.

GeoVax Labs In-Licenses Development Rights To Multi-Antigenic COVID-19 Vaccine Candidate

Phase 2 Vaccine Designed to Enhance Response for Immunocompromised Patients

GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope's COVID-19 Vaccine

Conference call to be held Thursday, November 11, at 4:30 p.m. Eastern Time

GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update

Single-dose of GEO-EM01 Provided 100% Protection in Lethal Challenge Evaluation

GeoVax Receives Notice of Allowance for Ebola Vaccine Patent

The stock price of Geovax Labs Inc (NASDAQ: GOVX) increased by over 3% during intraday trading today. This is why it happened.

News for Geovax Labs Stock (GOVX)